Bridgewater Associates’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,835
| Closed | -$1.18M | – | 1042 |
|
|
2026
Q1 | $1.18M | Sell |
6,835
-15,219
| -69% | -$2.82M | 0.01% | 764 |
|
|
2025
Q4 | $4.4M | Buy |
22,054
+2,146
| +11% | +$389K | 0.02% | 571 |
|
|
2025
Q3 | $3.11M | Buy |
+19,908
| New | +$3.16M | 0.01% | 610 |
|
|
2024
Q2 | – | Sell |
-1,100
| Closed | -$298K | – | 890 |
|
|
2024
Q1 | $298K | Sell |
1,100
-1,665
| -60% | -$398K | ﹤0.01% | 655 |
|
|
2023
Q4 | $654K | Sell |
2,765
-240
| -8% | -$47.2K | ﹤0.01% | 679 |
|
|
2023
Q3 | $589K | Sell |
3,005
-1,301
| -30% | -$267K | ﹤0.01% | 674 |
|
|
2023
Q2 | $905K | Buy |
4,306
+1,124
| +35% | +$224K | 0.01% | 586 |
|
|
2023
Q1 | $642K | Sell |
3,182
-263
| -8% | -$59.6K | ﹤0.01% | 614 |
|
|
2022
Q4 | $751K | Buy |
3,445
+1,392
| +68% | +$304K | ﹤0.01% | 677 |
|
|
2022
Q3 | $404K | Sell |
2,053
-3,553
| -63% | -$767K | ﹤0.01% | 798 |
|
|
2022
Q2 | $1.2M | Buy |
5,606
+666
| +13% | +$163K | 0.01% | 769 |
|
|
2022
Q1 | $1.4M | Buy |
4,940
+3,453
| +232% | +$1.06M | 0.01% | 755 |
|
|
2021
Q4 | $560K | Buy |
1,487
+838
| +129% | +$326K | ﹤0.01% | 637 |
|
|
2021
Q3 | $268K | Buy |
+649
| New | +$270K | ﹤0.01% | 647 |
|
|
2019
Q4 | – | Sell |
-3,406
| Closed | -$451K | – | 499 |
|
|
2019
Q3 | $451K | Buy |
+3,406
| New | +$457K | ﹤0.01% | 283 |
|
|
2019
Q1 | – | Sell |
-15,166
| Closed | -$1.72M | – | 354 |
|
|
2018
Q4 | $1.72M | Buy |
15,166
+12,120
| +398% | +$1.52M | 0.02% | 261 |
|
|
2018
Q3 | $410K | Sell |
3,046
-7,459
| -71% | -$921K | ﹤0.01% | 298 |
|
|
2018
Q2 | $1.18M | Sell |
10,505
-1,740
| -14% | -$188K | 0.01% | 235 |
|
|
2018
Q1 | $1.31M | Buy |
+12,245
| New | +$1.32M | 0.01% | 236 |
|
|
2017
Q4 | – | Sell |
-2,574
| Closed | -$278K | – | 265 |
|
|
2017
Q3 | $278K | Sell |
2,574
-4,135
| -62% | -$425K | ﹤0.01% | 275 |
|
|
2017
Q2 | $679K | Buy |
+6,709
| New | +$618K | 0.01% | 233 |
|
|
2016
Q1 | – | Sell |
-2,687
| Closed | -$216K | – | 268 |
|
|
2015
Q4 | $216K | Sell |
2,687
-17,000
| -86% | -$1.23M | ﹤0.01% | 254 |
|
|
2015
Q3 | $1.25M | Buy |
+19,687
| New | +$1.41M | 0.02% | 222 |
|
|
2015
Q2 | – | Sell |
-4,700
| Closed | -$373K | – | 330 |
|
|
2015
Q1 | $373K | Sell |
4,700
-500
| -10% | -$36.9K | ﹤0.01% | 264 |
|
|
2014
Q4 | $331K | Buy |
5,200
+1,000
| +24% | +$62.7K | ﹤0.01% | 278 |
|
|
2014
Q3 | $251K | Buy |
+4,200
| New | +$240K | ﹤0.01% | 339 |
|
Other funds holding CRL
AI
Bridgewater Associates's CRL Position: Q2 2026 in Review
Bridgewater Associates sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 6,835 shares — an estimated $1.18M sold.
Bridgewater Associates first reported a position in CRL in Q3 2014 and held it in 26 quarters. The position peaked at $4.4M in Q4 2025. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Bridgewater Associates reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
- Bridgewater Associates sold 6,835 Charles River Laboratories shares in Q2 2026, an estimated $1.18M.
- Bridgewater Associates first reported a position in Charles River Laboratories in Q3 2014 and held it in 26 quarters.
- Bridgewater Associates's Charles River Laboratories position peaked at $4.4M in Q4 2025.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.